Bioresorbable Polymer Medical Devices Market Global Report 2026

The bioresorbable polymer medical devices market size has grown strongly in recent years. It will grow from $1.64 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 7.0%.The growth in the historic period can be attributed to the increasing demand for minimally invasive medical interventions, rising preference for temporary implantable solutions, growing adoption of bioresorbable vascular technologies, increasing need to avoid secondary implant removal operations, and expanding utilization of biodegradable polymers in medical device applications.

The bioresorbable polymer medical devices market size is expected to see strong growth in the next few years. It will grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing demand for implants customized to individual patient requirements, rising adoption of resorbable orthopedic fixation solutions, growing need for controlled implant degradation rates, expanding clinical utilization of bioresorbable polymers, and increasing preference for biocompatible implant solutions designed for long-term performance. Major trends in the forecast period include increasing development of patient-specific bioresorbable implants, growing advancement in controlled polymer degradation technologies, expanding clinical use of bioresorbable vascular stents, rising development of next-generation biodegradable polymers, and increasing adoption of resorbable orthopedic fixation devices.

The increasing preference for minimally invasive surgical procedures is expected to propel the growth of the bioresorbable polymer medical devices market going forward. Minimally invasive surgical procedures refer to surgical techniques that use small incisions and specialized instruments to perform operations while minimizing tissue damage, postoperative pain, and recovery time. Minimally invasive surgical procedures are increasing due to growing patient preference for faster recovery, reduced postoperative pain, shorter hospital stays, and a lower risk of complications. Bioresorbable polymer medical devices facilitate these procedures by providing temporary tissue support and naturally degrading after the healing process, thereby eliminating the need for secondary removal surgeries. For example, in June 2025, according to NHS England, a UK-based government department, around 70,000 robot-assisted minimally invasive surgeries were performed across the NHS in 2023-24. The NHS aims to expand this to 500,000 procedures annually by 2035, with 90% of eligible keyhole surgeries expected to be robot-assisted, reflecting the growing adoption of minimally invasive surgical techniques. Therefore, the increasing preference for minimally invasive surgical procedures is driving the growth of the bioresorbable polymer medical devices market.

Key companies operating in the bioresorbable polymer medical devices market are focusing on developing advanced products, such as fully resorbable polymer-based implants, to improve tissue regeneration, provide temporary mechanical support, and eliminate the need for permanent implants or secondary removal surgeries. Fully resorbable polymer-based implants are medical implants made from polymers that are designed to gradually break down and be absorbed by the body after serving their intended purpose. For example, in February 2025, Atreon Orthopedics, a US-based orthopedic medical device company, received FDA 510(k) clearance and full market launch of BioCharge Autobiologic Matrix, a fully resorbable synthetic implant designed for rotator cuff repair. The bioresorbable polymer-based scaffold is engineered to reinforce tendon repair while stimulating the body's natural healing response, eliminating the need for permanent implants.

In June 2026, Olympus Corporation, a Japan-based medical technology company, acquired BioProtect Ltd. for $270 million. Through this acquisition, Olympus expanded its urological and oncology technology portfolio, strengthened its position in prostate cancer treatment, and obtained BioProtect’s biodegradable Balloon Spacer technology, which is designed to protect healthy tissue during radiation therapy for prostate cancer. BioProtect Ltd. is an Israel-based medical device company specializing in the development and manufacture of biodegradable and bioresorbable polymer balloon spacer implants.

Major companies operating in the bioresorbable polymer medical devices market are Abbott Laboratories, Medtronic plc, Stryker Corporation, Becton Dickinson and Company, Evonik Industries AG, W. L. Gore & Associates Inc., Zimmer Biomet Holdings Inc., Smith & Nephew plc, Terumo Corporation, B. Braun SE, Arkema S.A., Teleflex Incorporated, Kuraray Co. Ltd., Ashland Inc., Corbion N.V., CONMED Corporation, KLS Martin Group SE & Co. KG, Geistlich Pharma AG, Foster Corporation, Putnam Plastics Corporation, GUNZE Limited, Poly-Med Inc., botiss biomaterials GmbH, Inion Oy, Bioretec Ltd., Medprin Biotech GmbH, Acuitive Technologies Inc., REVA Medical Inc., BioCer Entwicklungs-GmbH.

North America was the dominating region in the bioresorbable polymer medical devices market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the bioresorbable polymer medical devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bioresorbable polymer medical devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.